Neural and Antidepressant Effects of Propofol



Status:Recruiting
Conditions:Depression
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 55
Updated:3/30/2019
Start Date:March 2019
End Date:July 2024
Contact:Kolby Leonardi
Email:kolby.leonardi@hsc.utah.edu
Phone:801-829-7382

Use our guide to learn which trials are right for you!

This study will compare the antidepressant effects of propofol versus a placebo intervention
while measuring potential treatment-related biomarkers.

Aim 1: Compare the clinical antidepressant effects of propofol versus placebo.

Aim 2: Characterize the effects of propofol on brain function and gene expression.

Inclusion Criteria:

- Age 18-55

- Diagnosis of major depressive disorder or bipolar disorder

- Current moderate-to-severe depressive episode

- Episode duration more than 2 months and less than 5 years

- Failure of at least 2 adequate antidepressant medication trials within the past 2
years

- Body mass index < 40

- 16-item Quick Inventory of Depressive Symptomatology, self-rated > 10

Exclusion Criteria:

- Contraindication to propofol or midazolam

- Daily use of benzodiazepine, opioid, ACE inhibitor, or ARB medication

- Symptomatic coronary artery disease or heart failure

- Poorly controlled hypertension or diabetes

- Abnormal kidney or liver function

- Pregnant or breast feeding

- Traumatic brain injury or significant neurologic signs (past year)

- Substance use disorder (past year)

- Obsessive compulsive disorder (current)

- Post-traumatic stress disorder (current)

- Schizophrenia-spectrum disorder (lifetime)

- Neurocognitive disorder (current)

- Personality disorder as a current focus of treatment

- ECT within the past 3 months

- Inappropriate for ECT, or poor response to ECT within the past 5 years

- Incompetent to provide consent
We found this trial at
1
site
Salt Lake City, Utah 84108
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials